REVOLADE works at the source of the disease
REVOLADE: Proven to overcome challenges with IST in first-line SAA1,9
In SAA, high levels of interferon-gamma inhibit TPO signaling that is essential for the maintenance and differentiation of hematopoietic stem and multipotent progenitor cells2
REVOLADE uniquely binds to the transmembrane domain of the TPO receptor and has been shown to bypass this inhibition1,9
By not competing with endogenous TPO, REVOLADE promotes stem-cell survival and differentiation, and neutrophil, erythrocyte, and platelet production9
EPO, erythropoietin; G-CSF, granulocyte colony-stimulating factor;
IST, immunosuppressive therapy; SAA, severe aplastic anemia; TPO, thrombopoietin.